Kala Pharmaceuticals
About
Kala Pharmaceuticals develops novel treatments for diseases that affect mucosal tissues.
- Waltham,Massachusetts,United States
- 101 - 250
- http://www.kalarx.com
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $31M
- Industries
- Biotechnology,Health Care,Medical,Pharmaceutical
- Founded date
- Jan 1, 2009
- Number Of Employee
- 101 - 250
- Operating Status
- Active
- Stock Symbol
- nasdaq:KALA
- Legal Name
- Kala Pharmaceuticals Inc.
- Also Known As
- Kala
Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high, sustained local drug concentrations with reduced systemic exposure and are delivered in a patient-friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept while establishing R&D collaborations with select partners to improve products in their pipelines.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 28, 2022 | Post-IPO Equity | $31M | — | — | — | Detail |
| Nov 29, 2021 | Post-IPO Equity | $16.12M | — | — | — | Detail |
| May 12, 2021 | Post-IPO Debt | $125M | 1 |
|
— | Detail |
| Apr 6, 2020 | Post-IPO Equity | $134M | — | — | — | Detail |
| Oct 3, 2018 | Post-IPO Equity | $110M | 1 |
Athyrium Capital Management LP
|
— | Detail |
Investments
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Dec 12, 2022
Public Pressure
|
Series Unknown | $6M | Blockchain | — |
|
Jul 4, 2022
AltLayer
|
Seed | $7.20M | Blockchain | — |
|
Jan 28, 2022
Astar Network
|
Series Unknown | $22M | Blockchain | — |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Post-IPO Debt |
|
Athyrium Capital Management LP
|
Yes | Post-IPO Equity |
Longitude Capital
|
Yes | Series C |
Ysios Capital
|
Yes | Series B |
CAM Capital
|
— | Series C |
Lux Capital
|
— | Series C |
OrbiMed
|
— | Series C |
Polaris Partners
|
— | Series C |
RA Capital Management
|
— | Series C |
Vivo Capital
|
— | Series C |
Employee Profiles
